Resistance limits the effectiveness of receptor tyrosine kinase (RTK)-targeted therapies.
0.1% Na deoxycholate, 0.1% SDS, and 140 mM NaCl, with protease and phosphatase inhibitor supplemented before use (BioRad). Protein concentration was normalized by bicinchoninic acid assay.
A bead-based multiplexed ELISA-based assay was used for signaling measurement (Bio- 
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AXL and a kinase dead variant K562R were amplified from previously used vectors (15) . Met and PDGFRb were amplified from pDONR223-PDGFRB and pDONR223-MET from William Hahn and David Root (Addgene plasmids 23893 & 23889) (16) . Each receptor was then cloned into IRES-EGFP2 (Clontech). Cells were seeded densely on 10 cm plates, and then transfected the next day with 5 μg of each plasmid with a corresponding amount of 5 μL Lipofectamine 2000 in OptiMEM according to manufacturer's instructions. After 4 hours, the media was exchanged into full serum media lacking antibiotics.
For evaluation of resistance-mediated selection, the day after transfection cells were split into 6 well plates and, after adhering, were placed in serum free media with inhibitor and GF as indicated. The next and following day, wells were trypsinized, spun down, and then
Research. For evaluating receptor overexpression, cells were trypsinized the day after transfection and fixed in 4% PFA in PBS for 1 hour, blocked in Odyssey Blocking Buffer (Li-Cor) for 1 hour, then stained with antibodies against Met, AXL, or PDGFRb overnight. The next day, cells were repeatedly washed and stained with Alexa-594 conjugated anti-mouse antibodies for 1 hour.
After additional washing, fluorescence, forward scatter, and side scatter were immediately quantified on an Accuri C6 (BD Biosciences).
Results

RTK expression is essential but not sufficient for bypass resistance
To better understand the process of bypass resistance and its relationship to signaling network state we first selected two HER2-overexpressing breast carcinoma cell lines, both studied before for their sensitivity to the HER2-targeted inhibitor lapatinib and their capacity for bypass resistance in the presence of HRG (6). We treated each cell line with 0, 1, or 5 μM of lapatinib either alone or in the presence of 50 ng/mL of different growth factors (GFs) ( Figure 1A ). Cells exhibited a dose-dependent decrease in viability measured at 72 hours strongly counteracted by simultaneous addition of HRG and partially by other GFs ( Figure 1B ). To expand our perspective beyond HER2-dependent signaling dysregulation, we additionally selected two EGFR-dependent lung adenocarcinoma cell lines, PC9 and HCC827, that are accordingly sensitive to the EGFR inhibitor erlotinib. We measured viability with 0 or 1 μM erlotinib in the presence of 50 ng/mL of different GFs ( Figure 1C ). Particular GFs counteracted the erlotinibinduced decrease in viability in a consistent pattern to that observed previously (6).
Because of manifold bypass possibilities among RTKs and their critical function in diverse biological processes, prospective diagnostic measurements are needed to identify which among many targeted therapies would be most effective to apply in precise combination to overcome bypass resistance. A first notion might be to measure and focus on treating those receptors that are most abundant or most abundantly activated within a tumor (17). Therefore, we next sought to directly determine the relationship between receptor abundance and capacity to provide bypass resistance. We measured the absolute abundance of seven RTKs across four cell lines using a recombinant standard. RTK abundances varied across several orders of magnitude, and for many cases the RTK that provided primary drug sensitivity was not the most abundant receptor ( Figure S1A ). To test the relationship between RTK abundance and resistance-promoting capacity (viability with inhibitor and growth factor normalized to that with just inhibitor), we plotted viability in the presence of inhibitor against the abundance of different GF-activated RTKs ( Figure 1D & 1E) . Each data point indicates RTK abundance matched to the viability promoting effect upon treatment with each cognate GF ( Figure 1A ). The viability of cells in the absence of erlotinib or lapatinib was predominantly dependent on EGFR or HER2 signaling, respectively. Therefore, we plotted in green the abundance of the inhibitor-targeted RTK and cell viability in the absence of inhibitor. While abundance significantly correlated with resistance capacity in the case of three cell lines, no significant correlation was observed for the HCC827 ( Figure 1D & 1E) in its resistance-conferring capacity ( Figure 1D ), while it was less potent than predicted in EGFRdependent cell lines ( Figure 1E ).
We considered that drug treatment or sustained serum withdrawal may influence RTK expression and thus the correlations we observed. For example, if HER2/HER3 expression is lost by either manipulation in PC9 cells, the change would explain the relative resistance-promoting inefficiency of HRG. Thus, we examined the influence of each over 24 hours in PC9 cells ( Figure   1F ). Only HER3 changed in abundance more than 2-fold, increasing up to 7-fold at 24 hours.
This change in fact exacerbates the discrepancy and removes the correlation between viability and abundance ( Figure 1E , tan line; r = 0.84, p < 0.05 to r = 0.62, p > 0.05). While more modest in effect, EGFR and MET displayed a simultaneous decrease of roughly 2-fold in abundance by 24 hours with serum withdrawal, or increase of 50% in the presence of 1 μM erlotinib ( Figure   S1B ). Therefore, inhibitor-induced changes in RTK abundance only reduced the correlation between RTK abundance and resistance-promoting capacity in the case of PC9 cells.
Despite mixed correlation between RTK abundance and resistance capacity within cell lines, we did observe a consistent threshold effect across all four cell lines, wherein all receptors that promoted resistance more than 30% were more abundant than 2×10 6 per cell ( Figure 1G ). We defined resistance promotion as the GF-induced increase in viability, scaled between 0.0 and 1.0, in order to compare across cell lines. To examine whether some threshold of expression might be necessary but not sufficient for resistance, we explored the results of two previous studies examining expression and ligand-induced resistance across a large number of cell lines (6,18). Similarly, we observed that expression below a certain level correctly predicted that ligand-induced bypass resistance would not occur, but also that high receptor
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RTK overexpression identifies qualitative differences in resistance-promoting capacity
The four cell lines of the present study were selected based on their sensitivity to an RTKtargeted therapy and ability to display resistance upon the addition of one or more GFs (6). We applied generalized linear regression modeling, regressing our phosphorylation measurements against viability, to understand which phosphorylation sites could predict the particular GF conditions leading to resistance. In order to capture dependencies on coordinate pathway activation, we included an interaction term of Akt and Erk. We elected to not include other interaction terms, or more complex relationships, due to less prior evidence implicating the other pathways measured. In the EGFR-dependent cell lines PC9 and HCC827, pcJun (and pErk for HCC827) was identified as particularly important ( Figure 3C Figure 3C ). In total, these results indicate that measurement of sustained pcJun and Erk pathway activation is necessary for accurate prediction of bypass resistance in PC9 cells.
Validation of the bypass resistance model identifies combination therapy approaches
With confidence that pcJun and Erk pathway activation were coordinately necessary for predicting bypass resistance development in PC9 cells, we sought to determine whether this interaction might suggest effective therapeutic combinations. We first measured the pathways influenced by treatment with a Mek inhibitor U0126 to ensure that pcJun was not simply responding to Erk activation. While Erk1/2 phosphorylation was completely abrogated by Mek inhibition, cJun phosphorylation was only modestly reduced in PC9, and not at all in HCC827 ( Figure 5A & S4A) . pcJun was most reliably and strongly abrogated by JNK inhibition ( Figure   S4A ), however total cJun levels also varied, indicating this phosphorylation measurement is likely a measure of both protein abundance and phosphorylation changes ( Figure S5 ). Thus, pcJun is most prominently modulated by JNK activity in these cells but is also influenced by Erk activity.
A first prediction of our model is that Erk and JNK inhibition would have additive effectiveness in decreasing PC9 viability ( Figure 3D ). Indeed, we observed that combination In contrast to the case with EGFR-dependent cells, our models of signaling-viability relationship for HER2-dependent cell lines indicated that JNK inhibition should in fact increase viability ( Figure 3D ). To test this, we first examined the effect of JNK inhibition on viability in the presence or absence of lapatinib, and as predicted observed a dose-dependent increase ( Figure   5G ). We wondered if this effect could modulate the ability of particular GFs to provide resistance in HER2-dependent cell lines. In particular, while lapatinib is thought to be an EGFR/HER2 dual-targeting inhibitor, we observed potent STAT3 phosphorylation suggestive of EGFR activation with EGF-treatment in each HER2-dependent cell line, and an increase in STAT3 phosphorylation with lapatinib treatment ( Figure 5H ). This indicated that some amount of EGFR signaling must be maintained in the presence of lapatinib. With respect to Akt phosphorylation, while more modest than HRG treatment, EGF treatment increased Akt phosphorylation roughly 4-fold in the presence of lapatinib ( Figure 5I ). We predicted that this increase in Akt phosphorylation may have more pronounced effects in the presence of JNK inhibition. While EGF treatment only lead to a modest increase in viability in the absence of JNK inhibition, with JNK inhibition the GF was able to make BT474 cells completely resistant to lapatinib ( Figure 1B & 5J). This indicates that JNK pathway activity strongly modulates the bypass signaling response of cells, and that our model accurately captures these effects through measurement of pcJun.
Discussion
While targeted therapies lead to survival benefits in patients, these benefits are usually shortlived due to resistance mechanisms. Many studies have focused on various mechanisms of resistance with the notion that identifying particular resistance mechanisms would lead to results suggest that RTK bypass resistance often corresponds to reactivation of the particular pathways lost by inhibitor treatment, resembling intracellular signaling in the absence of inhibitor (e.g. HRG in BT474 & SKBR3, Figure 3A) . Particular RTKs can provide measurable signaling responses and yet fail to produce resistance due to mismatch between the requisite and provided signaling changes ( Figure 4A ). An outstanding question is whether more global transcriptional mechanisms of resistance, such as epithelial-mesenchymal transition, operate through fundamental changes in the pathways relied on for survival, or if other factors such as RTK expression changes still lead to activation of the same survival pathways (29). The many pathways involved in the development of resistance will necessitate modeling approaches such as those undertaken here to address these mechanisms. Research. 
